Concepedia

CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy

Sophie E. Mayer, Noel S. Weiss, Jessica Chubak, David R. Doody, Christopher S. Carlson, Karen W. Makar, Michelle A. Wurscher, Kathleen E. Malone

Cancer Causes & Control · 2018 · 13 citations · 45 references

DOI

Concepts

References

45

Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer

Reiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama et al. · Oncology · 2013 · 13.2K citations · Full text

, , +17

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

The Lancet · 2011 · 3.1K citations · Full text

, , +15

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

, , +14

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

Zeruesenay Desta, Vered Stearns, Brent B. Ward et al. · JNCI Journal of the National Cancer Institute · 2005 · 942 citations · Full text

, , +17

Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

Vered Stearns · JNCI Journal of the National Cancer Institute · 2003 · 849 citations · Full text

, , +17